LGNDZ
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.67 | $52M | $48M |
| 2025 Q4 | 2.27 | $60M | $46M |
| 2025 Q3 | 6.07 | $115M | $13M |
| 2025 Q2 | 0.25 | $48M | $16M |
| 2025 Q1 | -2.21 | $45M | -$26M |
| 2024 Q4 | -1.70 | $43M | $28M |
| 2024 Q3 | -0.39 | $52M | $40M |
| 2024 Q2 | -2.88 | $42M | $11M |